USS Investment Management Ltd Has $4.95 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

USS Investment Management Ltd cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,824 shares of the medical equipment provider's stock after selling 14,768 shares during the period. USS Investment Management Ltd's holdings in Zimmer Biomet were worth $4,945,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. HB Wealth Management LLC grew its stake in Zimmer Biomet by 5.9% during the fourth quarter. HB Wealth Management LLC now owns 4,302 shares of the medical equipment provider's stock worth $455,000 after buying an additional 241 shares in the last quarter. Ballentine Partners LLC lifted its holdings in shares of Zimmer Biomet by 18.6% during the 4th quarter. Ballentine Partners LLC now owns 4,571 shares of the medical equipment provider's stock worth $483,000 after acquiring an additional 716 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 63,099 shares of the medical equipment provider's stock worth $6,680,000 after acquiring an additional 729 shares in the last quarter. Dakota Wealth Management increased its stake in Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after acquiring an additional 122 shares during the last quarter. Finally, Brighton Jones LLC acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $204,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.1%

Zimmer Biomet stock traded down $1.05 during mid-day trading on Wednesday, hitting $93.16. 284,223 shares of the stock were exchanged, compared to its average volume of 1,792,006. The stock has a market capitalization of $18.43 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $117.45. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm's fifty day simple moving average is $101.09 and its two-hundred day simple moving average is $105.13.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period in the prior year, the firm posted $1.94 EPS. The company's quarterly revenue was up 1.1% on a year-over-year basis. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZBH. Royal Bank of Canada decreased their price target on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JMP Securities reduced their price objective on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Raymond James lowered their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $111.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.